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Abstract Prohormones such as dehydroepiandrosterone
(DHEA) are steroid precursors that do not show hormonal
activity by themselves. Abuse of these prohormones in
cattle fattening is hard to prove because of strong in vivo
metabolism and the difficulty to detect metabolites which
are not significantly above endogenous levels. The aim of
the present work was to develop an in vitro assay capable
of detecting the indirect hormonal activity of prohormones
that might be present in feed supplements and injection
preparations. Sample extracts were incubated with a bovine
liver S9 fraction in order to mimic the in vivo metabolic
activation. Subsequently incubated extracts were exposed to
a highly androgen-specific yeast bioassay to detect hormonal
activity. Metabolic activation of DHEA, 4-androstene-3,17-
dione (4-adione) and 5-androstene-3,17-diol (5-adiol)
resulted in an increased androgenic activity caused by the
formation of the active androgen 17β-testosterone (17β-T),
as shown by ultra-performance liquid chromatography and
time-of-flight mass spectrometry with accurate mass mea-
surement. The developed in vitro system successfully mimics
the hydroxysteroid dehydrogenase (HSD)- and cytochrome
P450-mediated in vivo metabolic transitions, thus allowing
assessment of both bioactivity and chemical identification
without the use of animal experiments. Screening of
unknown supplement samples claimed to contain DHEA
resulted in successful bioactivation and positive screening
results according to the androgen yeast biosensor.
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Introduction
Within the European Union the use of growth-promoting
agents in cattle fattening is banned according to EC
directive 96/22 [1]. Interestingly, there is not a black list
of substances but EC 96/22 states that all substances having
thyrostatic, estrogenic, androgenic or gestagenic activity are
prohibited. A trend has been observed from the abuse of
synthetic steroids towards natural steroid esters and
prohormones. Feed supplements and preparations contain-
ing prohormones have the potential to enhance the levels of
natural occurring steroids and can be misused in livestock
production. After administration and uptake in the blood
circulation, peripheral tissues are able to metabolize prohor-
mones into more biologically active androgens and estro-
gens [2–4]. With respect to androgens this leads to anabolic
action and subsequently to increased body weight, muscle
strength and improved lean/fat ratios in farm animals [5].
Abuse of prohormones in livestock production is hard to
prove: urinary metabolites are unknown or not significantly
above highly fluctuating endogenous levels [6]. Chemical
methods have the drawback of detecting only targeted
compounds of interest. Biological transcription activation
assays, however, have the advantage of detecting compounds
based on bioactivity. For screening of hormones a wide range
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of mammalian or yeast cell-based bioassays have been
developed [7–10]. These assays focus mainly on ligand–
receptor interactions in which activation of a specific receptor
is linked to a transcription reporter mechanism. Assays based
onmammalian cell lines are in general more sensitive; however,
the metabolic capacity of both mammalian and yeast cell-
based assays is rather limited [11–13]. The latter are relatively
easy to use and very robust, making them suitable for screening
of samples from practice without complex sample cleanup
procedures. In addition, yeast cells lack endogenous receptors
and thus lack the potential cross talk from other receptor types
[14]. As a result the signals obtained in the yeast androgen
bioassay may be associated only with the androgenic
properties of the compound or sample extract tested.
In vivo, hepatic first pass metabolism of exogenous and
endogenous compounds normally leads to inactivation by
phase I and phase II enzymes and the subsequent excretion
of the deactivated compounds. However, metabolism can
also result in an increased biological activity of a given
compound [15]. Prohormonal compounds can be activated
by hydroxysteroid dehydrogenases (HSDs). Prohormones
such as dehydroepiandrosterone (DHEA), 4-androstene-
3,17-dione (4-adione) and 5-androstene-3,17-diol (5-adiol)
are direct precursors of potent androgens like 17β-testos-
terone (17β-T) and dihydrotestosterone (DHT). The
3β-hydroxysteroid dehydrogenase/isomerase (3β-HSD) en-
zyme catalyzes the two-step conversion of 3β-hydroxyste-
roids, like DHEA and 5-adiol, into 4-adione and 17β-T,
respectively. 17β-Hydroxysteroid dehydrogenase (17β-
HSD) catalyzes the conversion of 17-ketosteroids, like DHEA
and 4-adione, into their corresponding 17-hydroxysteroids, 5-
adiol and 17β-T, respectively (Fig. 1). These conversions
yield an increase of biological activity in vivo [2–4]. The
action of biologically active androgens is mediated by the
androgen receptor (AR). Upon ligand binding, the AR
dissociates from its chaperone proteins and is translocated
in its active state to the nucleus ready to bind to androgen-
responsive elements (AREs) [16]. Binding results in recruit-
ment of coactivators and enhanced transcription of target
genes regulating androgenic-anabolic action.
In this context we explored the combined use of a bovine
liver S9-based bioactivationmodel and a previously developed
highly androgen-specific yeast assay based on the constitutive
expression of the human androgen receptor (hAR) in
combination with an androgen-responsive element coupled
to an enhanced green fluorescent protein (EGFP) reporter
system. A promising in vitro model for evidence of the indirect
hormonal activity of prohormones, in accordance with the
bioactivity-based legislation [1], has been developed. The
results obtained were supported by chemical identification of
the metabolites using ultra-performance liquid chromatogra-
phy (UPLC) and time-of-flight mass spectrometry (TOFMS).
Methods and materials
Chemicals
Dehydroepiandrosterone (DHEA), 5-androstene-3,17-diol (5-
adiol), 4-androstene-3,17-dione (4-adione), 17β-testosterone
Fig. 1 In vivo steroid hormone biosynthesis: side chain cleavage of
cholesterol results in pregnenolone which is metabolized into DHEA
under P450c17 activity. From DHEA, conversions are catalyzed by
3β-HSD and 17β-HSD activity resulting in formation of potent
androgens like 17β-T. Reversible reactions (marked by double
arrows) depend on cofactor availability (e.g. NADP/NADPH ratios).
Estrogens are formed from androgens (4-adione and 17β-T) by
aromatase activity
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(17β-T), 17α-testosterone (17α-T), 5α-dihydrotestos-
terone (DHT), 7α-hydroxy-DHEA (7α-OH-DHEA), 7β-
hydroxy-DHEA (7β-OH-DHEA), 16α-hydroxy-DHEA
(16α-OH-DHEA), 16β-hydroxy-DHEA (16β-OH-DHEA),
11β-hydroxy-DHEA (11β-OH-DHEA) and 19-hydroxy-
DHEA (19-OH-DHEA) were obtained from Steraloids
(Newport, RI, USA). Sodium acetate, sodium carbonate,
sodium chloride, di-sodium hydrogen phosphate dihydrate,
sodium dihydrogen phosphate monohydrate, ammonium
sulphate, magnesium chloride, potassium chloride, tris
(hydroxymethyl)aminomethane (Tris), dimethylsulfoxide
(DMSO), hydrochloric acid and acetic acid were purchased
from Merck (Darmstadt, Germany). Glucose-6-phosphate,
NADH disodium salt, NADP disodium salt and NADPH
tetrasodium salt were from Roche Diagnostics (Almere, the
Netherlands). Acetonitrile, methanol and isooctane were
obtained from Biosolve (Valkenswaard, the Netherlands).
Dextrose and yeast nitrogen base without amino acids and
without ammonium sulphate were from Difco (Detroit, MI,
USA). L-Leucine, bovine serum albumin (BSA), hydroxy-
steroid dehydrogenase originating from Pseudomonas tes-
tosteroni and NAD sodium salt were purchased from Sigma
(St. Louis, MO, USA). Water used for LC/MS was purified
using a Millipore (Bedford, MA, USA) Milli-Q system.
Preparation of liver S9 fractions
Four Frisian bovines (350–430 kg, 13–14 months old) that
served as normally fed negative controls in a 6-week animal
experiment were sacrificed at the end of the trial. At
sacrifice, liver tissue was rinsed with ice cold 0.9% sodium
chloride and snap-frozen in liquid nitrogen. Liver tissues
were homogenized in twice their volume of Tris-HCl buffer
(50 mM, pH 7.4, 1.15% KCl), using a blender. Homoge-
nates were pooled and centrifuged at 10,000 g for 25 min at
4 °C. The supernatant was snap-frozen in liquid nitrogen
and stored at −80 °C until use. Protein concentrations in
this S9 fraction were determined according to Lowry [17],
using the BioRad DC protein assay (BioRad, Veenendaal,
the Netherlands) and BSA as a standard. The animal
experiment referred to was approved by the Animal Ethics
Committee of Gent University, Belgium, in accordance
with local ethical requirements.
Prohormone incubations
Incubations of 50 µg (pro)hormones, or of 100 µl final SPE
eluent from supplement samples (see Extraction of supple-
ment samples), were carried out in a glass tube containing
0.1 M sodium phosphate buffer (pH 7.4), 10 mM glucose-
6-phosphate, 33 mM KCl, 8 mM MgCl2, 2 mg/ml bovine
S9 fraction and either 4 mM NAD, NADH, NADP or
NADPH. The final volume was 1 ml and the mixtures were
incubated at 37 °C in a water bath for 6 h. Single
incubations of prohormones and of SPE eluents were
performed. Blanks without bovine liver S9 and blanks
without cofactor were included to check for nonenzymatic
reactions during the incubation period. Reactions were
terminated at t=0 and t=6 h with 1 ml acetonitrile, and the
reaction products were subsequently subjected to a cleanup,
which is similar to a method described by Marwah et al.
[18]. In summary, the mixture was centrifuged for 15 min at
3,000 g, and the supernatant was transferred to a fresh glass
tube. The mixture was extracted again with 2 ml acetonitrile
and centrifuged for 10 min at 3,000 g. The combined
supernatants were evaporated under nitrogen at 45 °C to
approximately 0.5 ml. Next, the extract was diluted with
3 ml methanol, centrifuged for 15 min at 3,000 g and
evaporated at 45 °C under nitrogen until dryness. The
residue was dissolved in 200 µl methanol and, following
the addition of 1.8 ml water, applied onto a preconditioned
reversed-phase solid-phase extraction (SPE) cartridge
(Waters Oasis™ HLB, 3 cc, 6 mg). The cartridge was
washed twice with 2 ml water and eluted with 2 ml
methanol. The SPE eluent was evaporated under nitrogen at
45 °C and reconstituted in 2 ml acetonitrile. Aliquots of
200 µl of this final acetonitrile extract plus 50 µl 4%
DMSO were pipetted in a conical 96-well plate (Greiner
Bio-One, Germany) and evaporated overnight in a fume
cupboard to leave only DMSO the next day.
Extraction of supplement samples
Two authentic supplement samples were extracted. Accord-
ing to the labels, each capsule of supplement A contained
50 mg DHEA and 10 mg vitamin C in a base of rice flour,
and each capsule of supplement B contained 500 mg
Tribulus terrestris, 100 mg 4-androstenedione, 100 mg
DHEA, 100 mg lysine and 15 mg zinc amine acid chelate.
A 100-mg aliquot of each capsule was extracted according
to a method described by Bovee et al. [14]. In summary,
sample aliquots were mixed with 4 ml methanol and 4 ml
sodium acetate buffer (0.25 M, pH 4.8), sonicated for
10 min and mixed for 15 min in a head over head
apparatus. Samples were then centrifuged for 10 min at
3,000 rpm, and 4 ml of the supernatant was collected. The
pH of this supernatant was adjusted to pH 4.8 with 4 M
acetic acid and applied onto an SPE cartridge (Varian, Bond
Elut, C18, 500 mg, 3 ml), previously activated with 3 ml
methanol and 3 ml sodium acetate buffer. Next, the SPE
cartridge was washed with respectively 1.5 ml sodium
acetate buffer, 2 ml MilliQ water, 1.5 ml sodium carbonate
(10% w/v), 2 ml MilliQ water and 2 ml methanol/water
(50:50 v/v). The SPE cartridge was dried and eluted with
4 ml acetonitrile. The SPE eluent thus obtained was applied
onto an NH2 SPE cartridge (Isolute, 100 mg, 3 ml)
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previously activated with 4 ml acetonitrile. The run
through was collected and evaporated at 45 °C under
nitrogen and reconstituted in 4 ml acetonitrile. At this
point the SPE eluent is either measured directly in the
androgen yeast biosensor or bioactivated according to the
procedure as described in Prohormone incubations and
then measured by the androgen biosensor. Two sets of
spiked supplement samples were prepared to monitor the
extraction recovery (“spike before samples”) and the
potential presence of AR antagonists in the supplements
(“spike after samples”). 17β-Testosterone was added to
“spike before samples” (5 µg/g) before the sample preparation
step and to “spike after samples” (30 µM in DMSO, 2 µl)
prior to biosensor exposure.
Recombinant yeast androgen bioassay
Transformants of a Saccharomyces cerevisiae strain that
express the human androgen receptor (hAR) and an yEGFP
reporter system [10] were grown on selective minimal
medium plates supplemented with L-leucine. Minimal
medium consisted of yeast nitrogen base without ammoni-
um sulphate or amino acids (1.7 g/l), dextrose (20 g/l),
ammonium sulphate (5 g/l) and was supplemented with L-
leucine (6 mg/l). At day 1, 10 ml minimal medium
supplemented with L-leucine (MM/L) was inoculated with
a single colony and cultured overnight at 30 °C, in a
shaking incubator at 125 rpm. The next day, the overnight
culture was diluted in MM/L to an optical density (OD)
value between 0.04 and 0.06 at 630 nm. Aliquots of 200 µl
yeast suspension were added to each well of a 96-well
plate, already containing the DMSO extract of samples and
controls as described in Prohormone incubations. A
standard dose–response curve of 17β-testosterone was
included in each experiment. Plates were incubated at
30 °C for 24 h in a shaking incubator (125 rpm), and
fluorescence was measured (485-nm excitation, 530-nm
emission) using a Synergy™ HT multi-detection microplate
reader (BioTek Instruments Inc., USA). The OD of the
yeast was measured at 630 nm after 24 h to monitor for any
cytotoxic effects on the yeast cells.
UPLC–TOFMS assignment of substances formed
in metabolic bioactivation
Ultra-performance liquid chromatography (UPLC) was
performed on a Waters (Milford, MA, USA) Acquity
system containing a Waters Acquity BEH C18 1.7 µm,
2.1×50-mm column, with mobile phases (A) acetonitrile/
water/formic acid (10:90:0.2, v/v/v) and (B) acetonitrile/
water/formic acid (90:10:0.2, v/v/v), linearly increasing
from 20 to 46% B in 5 min at 0.7 ml/min. The column
temperature was 45 °C, and the injection volume 20 µl. The
column effluent was split 1:1 prior to mass spectrometry.
Mass spectrometry was performed on a Waters QTOF
micro instrument equipped with a dual electrospray
ionization (ESI) probe and operated in the positive ion
mode (ESI) at a source temperature of 120 °C, desolvation
temperature 350 °C, desolvation gas flow 700 l/h, ESI
capillary voltage of 3,000 V and a cone voltage of 30 V.
Phosphoric acid in acetonitrile/water (0.01:50:50, v/v/v)
was used as reference solution in the LockSpray™ at a flow
rate of 10 µl/min. TOF data were collected between m/z 80
and 1,200 and processed using Masslynx v 4.0 software.
Fig. 2 Dose–response curves of DHEA, 4-adione, 5-adiol, 17β-T and DHT after 24 h obtained in the androgen yeast biosensor. Fluorescence
signals are the mean of an assay triplicate (± SD) and corrected for the signal at t=0 and the blank DMSO
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Results and discussion
Direct androgen bioassay screening
Androgen bioassay dose–response curves of DHEA and
known in vivo metabolites 4-androstene-3,17-dione (4-
adione), 5-androstene-3,17-diol (5-adiol), 17β-testosterone
(17β-T) and 5α-dihydrotestosterone (DHT) are shown in
Fig. 2. Nonlinear regression curves were fitted through the
data points, and the concentration giving half the maximum
(EC50) was calculated. Exposure of the androgen reporter-
gene yeast bioassay to DHEA and 5-adiol did not result in a
response of the cells, i.e. no direct hormonal activity was
observed in vitro in accordance with expectations. In
contrast a direct androgenic activity was observed for 4-
adione, 17β-T and DHT, with EC50 values of 6,900 nM,
92 nM and 26 nM, respectively. It should be noted that the
obtained dose–response curve of 4-adione was also caused
by a 17β-T impurity (data not shown), apart from the
androgenic activity of 4-adione itself.
Incubation of prohormones with bovine liver S9 followed
by androgen bioassay screening
To study the bioactivation of prohormones, 50 µg of
DHEA, 4-adione and 5-adiol were incubated with a bovine
liver S9 mix in the presence of either NAD, NADH, NADP
or NADPH. Initially, trials were performed with incuba-
tions of DHEA with NAD and pure hydroxysteroid
dehydrogenase originating from Pseudomonas testosteroni
containing 3α- and 3β-HSD activity. Incubation of DHEA
for 1 h resulted in an increase of response in the androgen
yeast assay, caused by formation of 4-adione and 17β-T
(results not shown). However, further work was with
bovine liver S9 to include the entire species specific liver
metabolism.
Results for sample extracts incubated with the S9 mix
for 0 and 6 h in the presence of 4 mM cofactor and
subsequently screened for androgenic activity in the yeast
androgen bioassay are shown in Fig. 3. The androgen assay
showed no signal for DHEA at t=0, but after metabolic
activation of DHEA with S9 in combination with either
NAD, NADP or NADPH, an androgenic activity was
measured (Fig. 3a). Application of NADH as a cofactor,
however, caused only a slight increase in the bioactivity
signal.
The compound 4-adione is already androgenic without
metabolic activation. Assuming 100% recovery, the 50 µg
4-adione (containing the 17β-T impurity) without activa-
tion would result in a final concentration of 87,000 nM in
the well, and in accordance with Fig. 2 this resulted in a
maximal fluorescence response of about 800. After S9
treatment the signal increased up to maximal 1,200,
suggesting that metabolites are formed that are more active
than 4-adione itself (Fig. 3b). Figure 3c shows that 5-adiol
can be activated by the S9/NAD combination, but no
changes in response were found after using NADH, NADP
and NADPH as a cofactor. Whether the differences in
response found between NAD and NADP are caused by
the high level of specificity of HSDs for either NAD
or NADP cannot be stated from the present study. The
blanks, without bovine liver S9 or cofactor, showed no
increase in response after 6-h incubation (results not
shown).
Bioactivation plus androgen bioassay screening
of supplement samples
Two supplements, A and B, were extracted and screened
directly in the yeast androgen bioassay (Fig. 4a and b). In
addition, aliquots of both supplements were spiked before
extraction with 5 µg 17β-T per gram sample in order to
Fig. 3 Androgen bioassay responses of a DHEA, b 4-adione and c 5-
adiol, before (t=0) and after (t=6) incubation with bovine liver S9 in
the presence of different cofactors. Fluorescence signals are the mean
of an assay triplicate (± SD) and corrected for the signal at t=0 and the
reagent blank
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check the recovery. Assuming no losses, the 17β-T spike
would result in a calculated concentration of 217 nM 17β-T
in the well. After sample cleanup but prior to the androgen
bioassay nonspiked sample aliquots were also spiked with
300 nM 17β-T in the well in order to investigate whether
there are any interfering or antagonistic compounds in the
extract. According to the dose–response curve shown in
Fig. 2, both 17β-T spikes are expected to give maximal
bioassay response. Supplement A, stated to contain mainly
DHEA, did not give a direct androgen bioassay response,
but also the 17β-T spike before and spike after controls
failed to give a response. Dilution of the extract, however,
resulted in an increase of the spike after control, suggesting
that the extract of this preparation contains an antagonist,
which could be DHEA. This is in line with earlier per-
formed quantitative structure–activity relationship (QSAR)
modeling approaches, where calculations of the free energy
after ligand docking and energy minimization of the
ligand–receptor complex were plotted against the relative
androgenic potency (RAP) [13]. DHEA showed no andro-
genic activity, but the calculated free energy is low,
suggesting a good binding to the androgen receptor. Thus,
DHEA shows affinity for the androgen receptor and might
compete with bioactive androgens explaining its antagonis-
tic properties. These antagonistic properties of DHEA were
confirmed in the androgen yeast bioassay by coexposure of
two concentrations of 17β-T, one concentration (70 nM) at
half maximum and a concentration (1,000 nM) at full
androgen bioassay response (data not shown).
Figure 4b shows that supplement B gives a direct
androgen bioassay response in accordance with the de-
clared ingredient 4-adione. This response remains at the
same level up to a 100-fold dilution of the extract, but at a
1,000-fold dilution the bioassay signal decreases. It should
be noted that the “spike after” control does not reach its
maximum fluorescence response of about 1,400 and that
following dilution of the samples the signal of the “spike
after” in the well increases. Again this is due to the
antagonistic effects of DHEA, which is also a declared
main compound in supplement B. Figure 4c shows the
androgen bioassay responses of supplement A and B in the
yeast androgen bioassay without and after the metabolic
activation with the S9/NAD combination. Supplement A
does not give a signal without the activation; however, after
6 h of incubation with bovine liver S9/NAD the signal
reaches near maximal response, indicating that bioactive
androgenic metabolites have been formed. As mentioned
before, supplement B already shows a response; however,
after the S9/NAD treatment the signal increases from about
600 to a near maximal response, again indicating that
androgenic metabolites have been formed. From these
results it can be concluded that supplement A contains
proandrogens showing antiandrogenic properties and sup-
plement B contains both androgens and proandrogens
containing androgenic and antiandrogenic properties.
UPLC–TOFMS analysis
UPLC–TOFMS analysis with accurate mass measurement
was used for the identification of the metabolites formed
after bovine S9 incubation. The metabolites were identified
by exact mass measurement and elemental composition
calculations thereof, followed by comparison of retention
times and mass spectra with the data obtained from
Fig. 4 Androgen bioassay responses of a supplement A and b
supplement B as well as spiked with 17β-T before (217 nM in the
well, calculated assuming 100% recovery) and after (300 nM added to
the well) extraction and cleanup procedure. Fluorescence signals are
the mean of an assay triplicate (± SD) and corrected for the signal at t
=0 and the reagent blank. c Androgen bioassay results after incubation
using bovine liver S9 and cofactor NAD
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commercially available standards. Fifty-mDa window
reconstructed ion chromatograms were used, being an
appropriate window for elemental composition elucidation
with a limited chance of false negative results due to mass
shifts caused by coeluting isobaric compounds and/or
detector saturation [19]. After metabolic activation of
DHEA with bovine liver S9 and cofactor NAD (Fig. 5)
the main metabolites of DHEA (X) appeared to be 4-adione
Fig. 5 UPLC–TOFMS total ion current (a) and reconstructed
accurate mass chromatograms of DHEA (b), 4-adione (c), 5-adiol
(d), 17α- and 17β-T (e), 7α-OH-DHEA (f) and a possible hydroxy-
adione or keto-DHEA metabolite (g) using the accurate mass of the
[M+H]+ or [M+H−H2O]+ ion and a mass window of 0.05 Da.
Conditions: bovine liver S9 bioactivation using cofactor NAD and an
incubation time of 6 h
Evidence of the indirect hormonal activity of prohormones 423
(IX), 7α-OH-DHEA (II) and metabolite III at a retention
time of 0.95 min having an abundant ion at m/z 303 and
minor ions at m/z 285 and m/z 267 suggesting a keto-
metabolite of DHEA (e.g. 7-oxo-DHEA) or a hydroxy-
metabolite of 4-adione. Several minor abundant metabolites
eluted after 0.70, 1.07, 1.21, 1.52, 2.09 and 2.29 min of
which the last two appeared to be 5-adiol (VII) and 17β-T
(VIII), respectively. The identification of 17β-T and 4-
adione confirm the bioactivation of DHEA into androgenic
substances observed in the androgen bioassay. Metabolites I
and IV are most likely hydroxy-metabolites of DHEA
resulting in [M+H]+ ions at m/z 305 and [M−H2O+H]+ ions
at m/z 287. V and VI most likely are keto-metabolites of
DHEA or hydroxylated metabolites of 4-adione, showing
[M+H]+ ions at m/z 303 and [M−H2O+H]+ ions at m/z 285.
According to ref. [20] metabolism of DHEA employing
human liver S9 for 20 min (instead of bovine liver S9 for
6 h) resulted mainly in 7α-OH-DHEA, 7β-OH-DHEA, 7-
oxo-DHEA, 16α-OH-DHEA and 5-adiol depending on the
cofactor used; no androgenic metabolites like 4-adione and
17β-T were observed. The retention times of DHEA and its
metabolites with corresponding exact masses have been
summarized in Table 1. UPLC–TOFMS analysis showed
that the spectra of 5-adiol, DHEA and hydroxy-metabolites
generally were dominated by [M+H−H2O]+ and [M+H−
2H2O]
+ ions, whereas the base peak in the mass spectra of
4-adione and 17β-T was the [M+H]+ ion, as expected for 3-
keto-4-ene steroids [21].
Metabolic activation of 4-adione, containing a 17β-T
impurity, with bovine liver S9 resulted in an increase of
17β-T, thereby confirming the increase in androgen
bioactivity as observed in the bioassay. Interestingly 17α-
T was also formed. For 5-adiol, only metabolic activation
using NAD resulted in formation of small amounts 17β-T,
in accordance with the bioassay results in Fig. 3b. The fact
that DHEA is converted into 4-adione and 5-adiol and the
latter two into 17β-T supports that bovine liver S9 contains
3β-HSD/isomerase and 17β-HSD activity. The observed
hydroxy-metabolites of DHEA are due to P450 enzyme
activity. Indeed in vitro bovine S9 treatment can mimic the
in vivo conversions shown in Fig. 1.
UPLC–TOFMS analysis showed that supplement A
contained only DHEA which is in accordance with what
is declared on the label. Apart from the claimed DHEA and
4-adione, supplement B contained 17ββ-T and traces of
17α-T, which are possibly by-products formed during
production or storage. Metabolic activation of the supple-
ments showed similar metabolite profiles as obtained
during activation of DHEA and 4-adione standards, result-
ing in higher levels of 5-adiol and the more potent andro-
gens 4-adione and 17β-T (see Electronic Supplementary
Material).
Conclusions
This work has outlined the concept of a bioactivity
screening assay for prohormones using a combination of
bovine liver S9 bioactivation with androgen bioactivity
detection. The prohormone DHEA shows no direct andro-
genic activity in the androgen yeast biosensor but antian-
drogenic properties. On the other hand, DHEA, but also
4-adione and 5-adiol, can be converted by bovine S9 into
more potent androgens, resulting in an indirect androgenic
hormonal activity. The developed in vitro bioactivation
system successfully mimics the hydroxysteroid dehydroge-
nase (HSD)- and cytochrome P450-mediated in vivo
metabolic transitions, thus allowing assessment of the
indirect bioactivity and chemical identification without the
use of animal experiments. UPLC–TOFMS analysis con-
Table 1 UPLC–TOFMS analysis data of DHEA incubated for 6 hours with bovine liver S9/NAD
Retention time (min)a m/zb Elemental composition Identified metabolitesc
[M+H]+ [M−H2O+H]+ [M−2H2O+H]+ [M+H]+
I 0.70 305.2117 (−0.3) 287.2023 (1.2) 269.1928 (2.3) C19H29O3 –
II 0.91 – 287.2010 (−0.1) 269.1905 (0.0) C19H29O3 7α-OH-DHEA
III 0.95 303.1945 (−1.5) 285.1864 (0.9) 267.1781 (0.9) C19H27O3 –
IV 1.07 305.2077 (−4.0) 287.2038 (2.7) 269.1889 (−1.6) C19H29O3 –
V 1.21 303.1974 (1.4) 285.1855 (0.0) – C19H27O3 –
VI 1.52 303.1966 (0.6) 285.1858 (0.3) 267.1768 (1.9) C19H27O3 –
VII 2.08 – 273.2220 (0.2) 255.2126 (1.3) C19H31O2 5-Androstene-3,17-diol
VIII 2.29 289.2197 (2.9) – – C19H29O2 17β-Testosterone
IX 2.62 287.1981 (−3.0) – – C19H27O2 4-Androstene-3,17-dione
X 2.69 289.2160 (−0.8) 271.2049 (−1.3) 253.1947 (−0.9) C19H29O2 DHEA
a Experimental retention times
b Accurate masses of observed ions, with mass error versus the theoretical masses in mDa (in parenthesis)
c Compounds confirmed by comparison with a standard
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firmed that the tested prohormones are metabolized into the
androgenic active steroids 4-adione and 17β-T. In the same
manner other prohormones of androgenic bioactive com-
pounds requiring transformation by HSDs at the 3-position
and 17-position can be screened for e.g. the prohormones
19-norandrostenedione and 19-norandrostenediol are
expected to be converted into the potent anabolic andro-
genic steroid nandrolone by 3β-HSD/isomerase and 17β-
HSD activity. In conclusion we can state that the androgen
bioassay can be used for the screening of supplements for
the presence of androgens, antiandrogens and prohormones,
the last of these following liver S9 bioactivation. The
system developed is expected to be equally applicable to
prohormone preparations from sports doping.
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